ClinicalTrials.gg
Active, not recruitingNCT05002777LUMINA 2Updated Jun 5, 2026

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

A Phase 2 interventional study of rilzabrutinib in Warm Autoimmune Hemolytic Anemia (wAIHA), sponsored by Sanofi. Active, not recruiting at 27 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.

Enrollment
18th of 30
22 · median 24
Started
2021
with 5 others
Phase 2
14 of 31
1 open now
Registered
22nd of 31
by date
Lead sponsor
3 of 31
Sanofi

Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one is the 18th largest by enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2021, is one of 14 in phase 2, and was the 22nd registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, or all of them as a file.
02

Study summary

All participants will receive rilzabrutinib orally. The screening period is up to 28 days, followed by a treatment period of 24 weeks for Part A. Participants who complete Part A and are deemed eligible for Part B can continue in the Core Part B period followed by an Extended Part B period for up to 253 weeks.

There will be a 7-day safety follow-up period after receiving the last dose of study medication either in Part A (for those not eligible for Part B or early terminated) or Part B. In addition, each participant will be asked to attend an EOT-Core Part B visit when the last participant completes 52 weeks in Core Part B. The Extended Part B period will last for up to 253 weeks.

The study is currently in the Part B Extension segment.

03

Conditions studied

  • Warm Autoimmune Hemolytic Anemia (wAIHA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with a confirmed diagnosis of primary wAIHA or systemic lupus erythematosus (SLE)-associated wAIHA (without other SLE-related manifestations apart from cutaneous and musculoskeletal manifestations)
  • Participants who have previously failed to maintain a sustained response after treatment with .
  • (ECOG) performance status grade 2 or lower.
  • Up-to-date vaccination status as per local guidelines.
  • (BMI) >17.5 and \<40 kg/m2
  • All use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Core Part B

  • Evidence of treatment efficacy to rilzabrutinib as defined by achieving overall response during Part A.
  • Completion of Part A treatment period (24 weeks). Extended Part B
  • Completion of Core Part B period.

Exclusion criteria

Exclusion Criteria:

  • medical history or ongoing chronic illness that would jeopardize the safety of the participant or compromise the quality of the data derived from his or her participation in the study as determined by the Investigator.
  • Participants with medical history of lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for the past 3 years.
  • Secondary wAIHA from any cause including drugs, lymphoproliferative disorders (low-count monoclonal B-cell lymphocytosis is allowed), infectious or disease, or active hematologic malignancies. Participants with positive antinuclear antibodies but without a definitive diagnosis of an autoimmune disease are allowed.
  • Myelodysplastic syndrome.
  • Uncontrolled or active infection: Patients with positive HBsAg and/or HBV DNA.
  • infection.
  • Concurrent treatment with other experimental drugs or participation in another clinical trial with any drug within 30 days or 5 half-lives, whichever is greater, prior to treatment start.
  • Known allergy to any of the study medications, their analogues, or in the various formulations of any agent.

Part B only

  • Participants who receive any therapy during Part A known to be active in wAIHA.
  • Presence of unacceptable side effect(s) or toxicity associated with rilzabrutinib such that there is an unfavorable risk-benefit assessment for continued treatment with rilzabrutinib in the opinion of the Investigator and/or Sponsor.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Rilzabrutinib

    Oral rilzabrutinib 400 mg BID

    Drug: rilzabrutinib

Interventions

  • Pharmaceutical form: Tablet Route of administration: Oral

    Also known as: PRN1008/SAR444671

06

What researchers measure

Primary outcomes

  1. Part A: Proportion of participants with overall hemoglobin response

    Response is defined as an increase in hemoglobin (Hb) by ≥2 g/dL from baseline and an absence of transfusion in the last 7 days, without biochemical resolution of hemolysis at the time response is achieved and an absence of rescue medications during the last 4 weeks. Complete Response is defined as hemoglobin ≥11 g/dL (women) or ≥12 g/dL (men), no evidence of hemolysis (normal bilirubin, lactate dehydrogenase (LDH) , haptoglobin, and reticulocytes), and absence of transfusion in the last 7 days and an absence of rescue medications during the last 4 weeks.

    Time frame: By Week 24 in Part A

  2. Part B: Proportion of participants who maintain durable response achieved during Part A or achieve a durable response during Part B and have a hemoglobin response

    Durable response (Part B) is defined as Hb level ≥10 g/dL with an increase from baseline (Part A) of ≥2 g/dL on three consecutive scheduled visits during Week 24 to Week 50; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.

    Time frame: By Week 50 in Part B

Secondary outcomes

  1. Proportion of participants with durable hemoglobin response

    Durable response (Part A) is defined as Hb level ≥10 g/dL with an increase from baseline of ≥2 g/dL on three consecutive evaluable visits during the 24-week treatment period; with absence of transfusion and no rescue medication during the period of 3 consecutive visits and for at least 7 days (transfusions) and 4 weeks (rescue medication) prior to the first consecutive visit.

    Time frame: By Week 24 in Part A

  2. Median time from baseline to first hemoglobin response

    Time frame: From Day 1 to Week 24 in Part A

  3. Frequency of rescue therapy (any wAIHA-directed therapy other than predniso[lo]ne or transfusion) received

    Time frame: After Week 1 of treatment to Week 24 in Part A and Week 305 in Part B

  4. Change from baseline in FACIT-Fatigue scale score

    The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale is a 13-item questionnaire used to assesses self-reported fatigue and its impact on daily activities and function.

    Time frame: Until Week 24 in Part A and Week 305 in Part B

  5. Incidence of treatment emergent adverse events (TEAEs), serious TEAEs, adverse events of special interest (AESIs)

    Safety assessment including clinical laboratory evaluations, vital sign measurements and ECG

    Time frame: Until Week 24 in Part A and Week 305 in Part B

07

Study locations

27 sites
  • The Oncology Institute of Hope & Innovation Site Number : 8400006
    Cerritos, California 90703, United States
  • TOI Clinical Research LLC_ Cerritos_Investigational Site Number: 8400006
    Cerritos, California 90703, United States
  • TOI Clinical Research LLC_Glendale_Investigational Site Number: 8400006
    Glendale, California 91204, United States
  • TOI Clinical Research LLC_Long Beach_Investigational Site Number: 8400006
    Long Beach, California 90805, United States
  • University of Southern California_Investigational Site Number: 8400009
    Los Angeles, California 90033, United States
  • TOI Clinical Research LLC_Santa Ana_Investigational Site Number: 8400006
    Santa Ana, California 92705, United States
  • The Lundquist Institute_Investigational Site Number: 8400005
    Torrance, California 90502, United States
  • TOI Clinical Research LLC_ Whittier_Investigational Site Number: 8400006
    Whittier, California 90602, United States
  • Georgetown University Hospital_Investigational Site Number: 8400003
    Washington D.C., District of Columbia 20007, United States
  • Oncology & Hematology Associates of West Broward_Investigational Site Number: 8400002
    Tamarac, Florida 33321, United States
  • Massachusetts General Hospital_Investigational Site Number: 8400001
    Boston, Massachusetts 02114, United States
  • Hanush-Krankenhaus_Investigational Site Number: 0400001
    Vienna, 1140, Austria
  • Peking Union Medical College Hospital_Investigational Site Number: 1560002
    Beijing, 100005, China
  • Institute of hematology&blood diseases hospital_Investigational Site Number: 1560003
    Tianjin, 300020, China
  • Odense Universitetshospital Hæmatologisk Forskningsenhed_Investigational Site Number: 2080001
    Odense, 5000, Denmark
  • Klinik für Hämatologie und Stammzellentransplantation_Investigational Site Number: 2760001
    Essen, 45147, Germany
  • Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz_Investigational Site Number: 3480001
    Székesfehérvár, 8000, Hungary
  • Ospedale Giuseppe Moscati_Investigational Site Number: 3800002
    Avellino, 83100, Italy
  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"_Investigational Site Number: 3800003
    Meldola, 47014, Italy
  • Ospedale Maggiore Policlinico_Investigational Site Number: 3800001
    Milan, 20149, Italy
  • Hospital Universitario de Cruces_Investigational Site Number: 7240004
    Barakaldo, 48093, Spain
  • Hospital Clinic de Barcelona_Investigational Site Number: 7240001
    Barcelona, 08036, Spain
  • Hospital Universitario La Paz_Investigational Site Number: 7240003
    Madrid, 28046, Spain
  • Hospital Universitario Virgen del Rocío_Investigational Site Number: 7240002
    Seville, 41013, Spain
  • Leeds Teaching Hospitals NHS Trust_Investigational Site Number: 8260001
    Leeds, LS9 7TF, United Kingdom
  • Barts Health NHS Trust_Investigational Site Number: 8260005
    London, E1 2ES, United Kingdom
  • Imperial College Healthcare NHS Trust_Investigational Site Number: 8260002
    London, W2 1NY, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in May 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2021
First posted
Aug 12, 2021
StartActual
Dec 7, 2021
Primary completionActual
May 23, 2024
CompletionEst.
Dec 31, 2029
Results delay requested
May 19, 2025
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05002777
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Dec 7, 2021
Primary completion
May 23, 2024
Completion
Dec 31, 2029 (estimated)
Last update
Jun 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion